-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2017 to Q1 2024.
- Avalo Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $7K, a 12.5% decline year-over-year.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $14K, a 50% decline from 2022.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $28K, a 27.3% increase from 2021.
- Avalo Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $22K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)